Recombinant SARS-CoV-2 Spike S1 antibody (RBD)

Catalog No. ABIN6952616

Product Details anti-SARS-CoV-2 Spike S1 Antibody

Target: SARS-CoV-2 Spike S1

Antibody Type: Recombinant Antibody

Biological Activity: Active

Binding Specificity: RBD

Reactivity: SARS Coronavirus-2 (SARS-CoV-2)

Host: Human

Expression System: HEK-293 Cells

Clonality: Monoclonal

Conjugate: This SARS-CoV-2 Spike S1 antibody is un-conjugated

Application: ELISA, Neutralization (Neut)

Purpose: Anti-SARS-CoV-2 neutralizing antibody (Human IgG1)

Specificity: The product is specific for SARS-CoV-2 Spike Protein S1 subunit and its RBD domain, and can inhibit the interaction between SARS-CoV-2 Spike Protein RBD and ACE2.

Cross-Reactivity (Details): This product is a specific neutralizing antibody against SARS-CoV-2 Spike Protein RBD domain and no cross-reactivity was detected against SARS-CoV Spike protein. The cross-reactivity with other coronaviruses has not been tested yet.

Characteristics: Anti-SARS-CoV-2 Neutralizing Antibody, Human IgG1 recognizes the SARS-CoV-2 Spike Protein RBD domain and can inhibit the interaction between SARS-CoV-2 Spike Protein RBD and ACE2. It has not been tested with other coronovirus. It is expressed from human 293 cells (HEK293).

Purity: > 95 % as determined by SDS-PAGE.

Sterility: 0.22 μm filtered

Isotype: IgG1

Biological Activity Comment: IC50 = 1.47 μg/mL using SARS-CoV-2 Inhibitor screening Kit

Application Details

Application Notes: Optimal working dilution should be determined by the investigator.

Restrictions: For Research Use only

Handling

Format: Lyophilized

Buffer: Lyophilized from 0.22 μm filtered solution in PBS, pH 7.4 . Normally trehalose is added as protectant before lyophilization.

Storage: 4 °C,-20 °C,-80 °C

Storage Comment: For long term storage, the product should be stored at lyophilized state at -20°C or lower.
This product is stable after storage at:
4-8°C for 12 months in lyophilized state,
-70°C for 3 years under sterile conditions after reconstitution.

References for anti-SARS-CoV-2 Spike S1 antibody (ABIN6952616)

Wu, Wu, Wang, Liu, Chu, Jiang, Kwong, Chow, Li, Chen: "Microfluidic particle dam for direct visualization of SARS-CoV-2 antibody levels in COVID-19 vaccinees." in: Science advances, Vol. 8, Issue 22, pp. eabn6064, (2022) (PubMed).

Chouchane, Grivel, Farag, Pavlovski, Maacha, Sathappan, Al-Romaihi, Abuaqel, Ata, Ismail Chouchane, Remadi, Halabi, Rafii, Al-Thani, Marr, Subramanian, Shan: "Dromedary camels as a natural source of neutralizing nanobodies against SARS-CoV-2." in: JCI insight, (2021) (PubMed).

Munitz, Edry-Botzer, Itan, Tur-Kaspa, Dicker, Marcoviciu, Goren, Mor, Lev, Gottesman, Muhsen, Cohen, Stein, Qimron, Freund, Wine, Gerlic: "Rapid seroconversion and persistent functional IgG antibodies in severe COVID-19 patients correlates with an IL-12p70 and IL-33 signature." in: Scientific reports, Vol. 11, Issue 1, pp. 3461, (2021) (PubMed).

Apostolou, Kyritsi, Vontas, Loizou, Hadjilouka, Speletas, Mouchtouri, Hadjichristodoulou: "Development and performance characteristics evaluation of a new Bioelectric Recognition Assay (BERA) method for rapid Sars-CoV-2 detection in clinical samples." in: Journal of virological methods, Vol. 293, pp. 114166, (2021) (PubMed).

Leach, Miller, Bentley, Mattiuzzo, Thomas, McAndrew, Van Montfort, Rabbitts: "Implementing a method for engineering multivalency to substantially enhance binding of clinical trial anti-SARS-CoV-2 antibodies to wildtype spike and variants of concern proteins." in: Scientific reports, Vol. 11, Issue 1, pp. 10475, (2021) (PubMed).

Park, Bazzill, Son, Nam, Shin, Ochyl, Stuckey, Meagher, Chang, Song, Montefiori, LaBranche, Smith, Xu, Moon: "Lipid-based vaccine nanoparticles for induction of humoral immune responses against HIV-1 and SARS-CoV-2." in: Journal of controlled release : official journal of the Controlled Release Society, Vol. 330, pp. 529-539, (2020) (PubMed).

Xiong, Qu, Ciazynska, Hosmillo, Carter, Ebrahimi, Ke, Scheres, Bergamaschi, Grice, Zhang, Nathan, Baker, James, Baxendale, Goodfellow, Doffinger, Briggs: "A thermostable, closed SARS-CoV-2 spike protein trimer." in: Nature structural & molecular biology, Vol. 27, Issue 10, pp. 934-941, (2020) (PubMed).

Target Details for SARS-CoV-2 Spike S1

Target: SARS-CoV-2 Spike S1

Abstract: SARS-CoV-2 Spike S1 Products

Synonyms: E2 antibody, Surface Glycoprotein antibody, S antibody

Target Type: Viral Protein

Background: Protein S (PROS1) is glycoprotein and expressed in many cell types supporting its reported involvement in multiple biological processes that include coagulation, apoptosis, cancer development and progression, and the innate immune response. Known receptors bind S1 are ACE2, DPP4, CEACAM etc.. It's been reported that 2019-nCoV can infect the human respiratory epithelial cells through interaction with the human ACE2 receptor. The spike protein is a large type I transmembrane protein containing two subunits, S1 and S2. S1 mainly contains a receptor binding domain (RBD), which is responsible for recognizing the cell surface receptor. S2 contains basic elements needed for the membrane fusion.The S protein plays key parts in the induction of neutralizing-antibody and T-cell responses, as well as protective immunity.

Gene ID: 43740568

UniProt: P0DTC2